Xeptiva Therapeutics

  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trial
    • FAQs
  • News
    • See news
    • Press
  • Blog
  • Contact
  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trial
    • FAQs
  • News
    • See news
    • Press
  • Blog
  • Contact

Government Grant for Xeptiva Therapeutics and the Institut Pasteur de Montevideo

march 1, 2o22
read below
Picture

The National Agency for Research and Innovation (ANII) has awarded Xeptiva Therapeutics and the Institut Pasteur de Montevideo a new grant “Articulation between the Academy and the Productive Sector”.  The Grant was applied by both institutions in 2021 and was approved by the ANII to begin its execution in March 2022. 

The Project is entitled "Validation of the mechanism of action of an immunotherapy (vaccine) for the treatment of chronic pain in companion animals” and aims to deepen the understanding of the mechanisms of action through which the immunotherapies to treat chronic pain in dogs developed by the startup and the Institute work.  
The project constitutes a subsidy of 70% of the total amount assigned to the project contributed by ANII and 30% contributed by Xeptiva. The project will last 24 months, and it will be Dr. Emiliano Trias, Adjunct researcher at the Institut Pasteur and CSO of Xeptiva, who will be in charge of its scientific execution at the Institute's Neurodegeneration Laboratory.  

This governmental grant constitutes a fundamental support for Xeptiva since it will allow the company to acquire relevant knowledge about the immunotherapeutic products that have been developed for several years by the scientific team of the Institute and the company.  About Xeptiva  Xeptiva Therapeutics LLC is a clinical stage biotech company dedicated to the development of immunotherapies to threat conditions associated with chronic neuroinflammation in companion animals. 

The company was created with the mission to improve companion animal’s health span (quality of life) and lifespan (years of life) by developing simple, affordable, disruptive, and highly effective immunotherapies.  About the Institut Pasteur de Montevideo  The Institut Pasteur de Montevideo (IP Montevideo) is one of the most recent affiliates of the Institut Pasteur International Network (RIIP in French), composed of 33 independent centres located in five continents and united by the same values. 

Dedicated to scientific research in biomedicine, IP Montevideo is composed by high-tech scientific platforms in areas such as genomics, proteomics, bioinformatics, molecular and cellular biology; laboratories are open to young scientists’ research projects; it has become an international education centre with courses on the latest biological knowledge and state-of-the-art technologies; and promotes start-ups for the development of biotechnological applications   About ANII   The National Agency for Research and Innovation (ANII) is a government entity that promotes research and the application of new knowledge to the productive and social reality of Uruguay. 

ANII makes funds available to the public for research projects, national and international postgraduate scholarships and incentive programs for innovative culture and entrepreneurship, both in the private and public sectors. ANII developed the National System of Researchers, a program of economic incentives for national researchers categorized based on a strict evaluation system. He also created the Timbó Portal, which allows free access to all kinds of scientific publications from around the world for all Uruguayans. The ANII works as a mechanism for articulation and coordination between the actors involved in the development of knowledge, research and innovation.



COMPANY

About Us
Team

INNOVATION

Technology
Pipeline
Target diseases

clinical trial

NEWS

See News
Press releases

cONTACT

BLOG

© COPYRIGHT 2025.  ALL RIGHTS RESERVED.